Hims & Hers Health’s (HIMS) Sell Rating Reaffirmed at Citigroup

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS) in a research report report published on Thursday,Benzinga reports. Citigroup currently has a $27.00 price target on the stock.

A number of other equities analysts also recently issued reports on HIMS. Morgan Stanley downgraded Hims & Hers Health from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Truist Financial lifted their price target on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday, February 26th. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Finally, Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $37.23.

Hims & Hers Health Price Performance

Shares of HIMS opened at $34.32 on Thursday. The stock has a 50-day moving average of $37.45 and a 200-day moving average of $27.31. The company has a market cap of $7.63 billion, a PE ratio of 78.01 and a beta of 1.37. Hims & Hers Health has a one year low of $11.20 and a one year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 268,932 shares of Hims & Hers Health stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. The trade was a 61.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Michael Chi sold 17,303 shares of Hims & Hers Health stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $48.14, for a total transaction of $832,966.42. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at $9,319,952.14. This trade represents a 8.20 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,062,011 shares of company stock valued at $36,892,724. 17.71% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health during the third quarter worth $604,000. Royce & Associates LP lifted its position in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Hims & Hers Health during the third quarter worth $634,000. Finally, Blueshift Asset Management LLC lifted its position in shares of Hims & Hers Health by 834.8% during the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock worth $4,513,000 after acquiring an additional 218,804 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.